Update on the reimbursement process in France
(Thomson Reuters ONE) - (Lysaker, Norway, 29 July 2009) Navamedic ASA has been informed thatthe Transparency Committee in France has proposed that Glucomed shallbe reimbursed in France.The next steps will be the final approval by the French HealthMinistry and a price decision by the Economic Committee for HealthProduct (CEPS).The Transparency Committee decided to propose for reimbursement forGlucomed with one condition: A clinical study demonstrating thecapacity of Glucomed to reduce the consumption of NSAIDs amongosteoarthritis patients treated with Glucomed must be performedwithin 2 years. The reimbursement status will be reevaluated when thestudy is performed.Navamedic and its French partner are preparing for the requestedclinical study. A first step will be to evaluate the costs and how toperform the clinical study. More information will be given in theQ2-presentation August 19th.For further information, please contact:Bernt-Olav Røttingsnes, CFO Navamedic ASAE-mail: bor(at)navamedic.comOffice: +47 67 11 25 44Mobile: +47 91 34 70 21This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 29.07.2009 - 08:37 Uhr
Sprache: Deutsch
News-ID 4080
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 395 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Update on the reimbursement process in France"
steht unter der journalistisch-redaktionellen Verantwortung von
Navamedic ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
